Memory Perception Assessment in Central/Non-central Nervous System Cancers
NCT ID: NCT03975959
Last Updated: 2025-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
426 participants
INTERVENTIONAL
2019-05-10
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Indeed, PM errors are an important part of the aging memory complaints. The prevalence of self-reported PM failures is also significant among young adults, compared with self-reported retrospective memory (RM) failures .Yet, PM errors are major sources of frustration and embarrassment .
In oncology, recently investigated the self-reported memory complaints in a 80 case-healthy-control study breast patients . Subjective memory complaints were assessed using the Prospective and Retrospective Memory Questionnaire . Results from the Paquet et al. study show that all participants (i.e., both patients and matched-controls) reported more PM than RM failures in daily-life (p\<.001). Breast cancer patients reported more RM and PM failures than controls. However, this group effect was no longer statistically significant when controlling for depression and fatigue.
These findings are consistent with the view that memory complaints are closely associated with depression and cancer-related fatigue, and more generally with psychopathological variables .As underlined by Paquet et al. subjective memory complaints should be investigated because they refer to some aspects of the cancer experience that could potentially be linked to quality of life. Thus, it is important to explore psychopathological basis such as depression, anxiety and fatigue while investigating self-reported memory failures in cancer patients.
Despites the importance of PM, there have been, to our knowledge, only few studies evaluating PM complaints or PM functioning in patients diagnosed with an intracerebral tumor (such as Diffuse Low-Grade Glioma- DLGG- or glioblastome- GB) or extra-cerebral tumor (such as breast cancer - BC). Therefore, the investigators thought it would be useful, as a first step, to conduct a study to explore and to manage the PM and RM subjective complaints in cancer patients compared to another chronic disease, such as HIV. In fine, these data will help to identify a new target for psychological management focused on either psychopathological or neuropsychological rehabilitation
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging
NCT01332916
Effect of Irradiation of the Cavernous Sinus and the Sellar Region on Autobiographical Memory
NCT02750371
Prospective Memory Imaging
NCT01638884
Cerebral Substrates of Prospective Memory in Young and Its Disruption in Normal Aging and in Alzheimer's Disease: A Study in Anatomical MRI, Diffusion Tensor MRI and Functional MRI
NCT02522091
Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
NCT03342586
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will aim at determining the nature of subjective memory complaints (i.e., prospective or retrospective memory) in cancer patients with intra- cerebral tumors (Glioblastomas and Diffuse Low Grade Gliomas) and extra cerebral tumors (Breast cancer) compared with controls.
The protocol administration will take about 20 minutes. It will be conducted by an experienced clinical neuropsychologist or clinical oncologist in each center during standard care. According to the results on the questionnaires and test, patients will be addressed and managed by a neuropsychologist, a clinical psychologist, psychiatrist or a speech therapist.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
FACTORIAL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GLIOBLASTOMA
One visit with collection :
demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test
QMRP questionnaire
a single consultation for test and questionnaires for a duration of 20 minutes
glioma
One visit with collection :
demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test
QMRP questionnaire
a single consultation for test and questionnaires for a duration of 20 minutes
breast cancer
One visit with collection :
demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test
QMRP questionnaire
a single consultation for test and questionnaires for a duration of 20 minutes
healthy
One visit with collection :
demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test
QMRP questionnaire
a single consultation for test and questionnaires for a duration of 20 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QMRP questionnaire
a single consultation for test and questionnaires for a duration of 20 minutes
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be aged of 18 to 80 years old
* Have a ECOG Performance Status ≤ 2 or a Karnofsky index ≥ 50 %
* Have a satisfactory level of French
* Have signed the informed consent
Also, for the DLGG group, the patients must:
* Have a histologically-proven diagnosis of DLGG (i.e., WHO grade II glioma)
* Receive or have received a first oncological treatment after surgery (chemotherapy, radiation therapy…)
Also, for the GB group, the patients must:
\- Have a histologically-proven diagnosis of GB (i.e., WHO grade IV glioma).
Also, for the breast cancer group, the patients must:
\- Have a histologically-proven diagnosis of breast cancer diagnosed \< 2 years.
Exclusion Criteria
* Patients under tutorship or curatorship or protective measures
* Patients suffering from sensorial or motor deficits avoiding the tests administration
* Patients with a reported history of psychiatric disease (e.g., mental retardation, psychotic disorders, learning disabilities, attention-deficit/hyperactivity disorder, and bipolar disorder)
* Have reported a substance dependence within the past six months (e.g., cocaine or methamphetamine dependence)
* Pregnant women
* Legal incapacity or physical, psychological social or geographical status interfering with the patient's ability to sign the informed consent or to terminate the study
Also, for the DLGG group, the patients must not:
* Have an anaplastic glioma (i.e., WHO grade III glioma)
* Have a DLGG with radiological or histological signs of anaplastic transformation
* Have a history of HIV
* Have a history of other cancer
Also, for the GB group, the patients must not:
* Patients treated with ≥2 lines of systemic cancer treatment (e.g., patient after the first GB recurrence)
* Have a history of HIV
* Have a history of other cancer
Also, for the breast cancer group, the patients must not:
* Have a metastatic disease
* Have a neoadjuvant therapy
* Have a documented neurological, or substance use disorders.
* Have a history of HIV
* Have a history of other cancer
* Have reported a history of neurological diagnoses (e.g., seizure disorders, closed head injuries with loss of consciousness greater than 15 min).
Also for the control group, the participants must not:
* Have a documented neurological, or substance use disorders
* Have a history of cancer
* Have a history of HIV
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut du Cancer de Montpellier - Val d'Aurelle
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guerdoux Estelle, MD
Role: STUDY_CHAIR
ICM Co. Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Icm Val D'Aurelle
Montpellier, Herault, France
CHU D'amiens
Amiens, Nord, France
UFR de Psychologie Université de Lille
Villeneuve-d'Ascq, NORD, France
Hôpital d'Instruction des Armées
Clamart, , France
Hopital saint Louis
Paris, , France
CHU Lyon
Saint-Genis-Laval, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bedard M, Verma S, Collins B, Song X, Paquet L. Prospective memory impairment in chemotherapy-exposed early breast cancer survivors: Preliminary evidence from a clinical test. J Psychosoc Oncol. 2016 Jul-Aug;34(4):291-304. doi: 10.1080/07347332.2016.1181133. Epub 2016 Apr 28.
Boone M, Roussel M, Chauffert B, Le Gars D, Godefroy O. Prevalence and profile of cognitive impairment in adult glioma: a sensitivity analysis. J Neurooncol. 2016 Aug;129(1):123-30. doi: 10.1007/s11060-016-2152-7. Epub 2016 May 30.
Brem S, Meyers CA, Palmer G, Booth-Jones M, Jain S, Ewend MG. Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers. Cancer. 2013 Nov 1;119(21):3830-8. doi: 10.1002/cncr.28307. Epub 2013 Aug 23.
Cheng H, Yang Z, Dong B, Chen C, Zhang M, Huang Z, Chen Z, Wang K. Chemotherapy-induced prospective memory impairment in patients with breast cancer. Psychooncology. 2013 Oct;22(10):2391-5. doi: 10.1002/pon.3291. Epub 2013 May 15.
Crawford JR, Henry JD, Ward AL, Blake J. The Prospective and Retrospective Memory Questionnaire (PRMQ): latent structure, normative data and discrepancy analysis for proxy-ratings. Br J Clin Psychol. 2006 Mar;45(Pt 1):83-104. doi: 10.1348/014466505X28748.
de Frias CM, Dixon RA, Backman L. Use of memory compensation strategies is related to psychosocial and health indicators. J Gerontol B Psychol Sci Soc Sci. 2003 Jan;58(1):P12-22. doi: 10.1093/geronb/58.1.p12.
Dieckmann P, Reddersen S, Wehner T, Rall M. Prospective memory failures as an unexplored threat to patient safety: results from a pilot study using patient simulators to investigate the missed execution of intentions. Ergonomics. 2006 Apr 15-May 15;49(5-6):526-43. doi: 10.1080/00140130600568782.
Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000 Dec 12;55(11):1621-6. doi: 10.1212/wnl.55.11.1621.
Fleming J, Ownsworth T, Doig E, Hutton L, Griffin J, Kendall M, Shum DH. The efficacy of prospective memory rehabilitation plus metacognitive skills training for adults with traumatic brain injury: study protocol for a randomized controlled trial. Trials. 2017 Jan 5;18(1):3. doi: 10.1186/s13063-016-1758-6.
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6. No abstract available.
Gentile S, Delaroziere JC, Favre F, Sambuc R, San Marco JL. Validation of the French 'multidimensional fatigue inventory' (MFI 20). Eur J Cancer Care (Engl). 2003 Mar;12(1):58-64. doi: 10.1046/j.1365-2354.2003.00295.x.
Gonneaud J, Kalpouzos G, Bon L, Viader F, Eustache F, Desgranges B. Distinct and shared cognitive functions mediate event- and time-based prospective memory impairment in normal ageing. Memory. 2011 May;19(4):360-77. doi: 10.1080/09658211.2011.570765.
Guerdoux E, Dressaire D, Martin S, Adam S, Brouillet D. Habit and recollection in healthy aging, mild cognitive impairment, and Alzheimer's disease. Neuropsychology. 2012 Jul;26(4):517-33. doi: 10.1037/a0028718. Epub 2012 May 28.
Guerdoux E, Martin S, Dressaire D, Adam S, Brouillet D. [Memory controlled processes between the young and old: the birth of cognitive complaint?]. Can J Aging. 2009 Mar;28(1):5-20. doi: 10.1017/S0714980809090023. French.
Herrmann C. International experiences with the Hospital Anxiety and Depression Scale--a review of validation data and clinical results. J Psychosom Res. 1997 Jan;42(1):17-41. doi: 10.1016/s0022-3999(96)00216-4.
Kim HJ, Barsevick AM, Fang CY, Miaskowski C. Common biological pathways underlying the psychoneurological symptom cluster in cancer patients. Cancer Nurs. 2012 Nov-Dec;35(6):E1-E20. doi: 10.1097/NCC.0b013e318233a811.
Kliegel M, Altgassen M, Hering A, Rose NS. A process-model based approach to prospective memory impairment in Parkinson's disease. Neuropsychologia. 2011 Jul;49(8):2166-77. doi: 10.1016/j.neuropsychologia.2011.01.024. Epub 2011 Jan 19.
Kliegel M, Martin M, McDaniel MA, Einstein GO. Varying the importance of a prospective memory task: differential effects across time- and event-based prospective memory. Memory. 2001 Jan;9(1):1-11. doi: 10.1080/09658210042000003.
Kvavilashvili L, Kornbrot DE, Mash V, Cockburn J, Milne A. Differential effects of age on prospective and retrospective memory tasks in young, young-old, and old-old adults. Memory. 2009 Feb;17(2):180-96. doi: 10.1080/09658210802194366.
Lange M, Joly F. How to Identify and Manage Cognitive Dysfunction After Breast Cancer Treatment. J Oncol Pract. 2017 Dec;13(12):784-790. doi: 10.1200/JOP.2017.026286.
Martin S, Mazzocco C, Maury P, Grosselin A, Van der Elst W, Dixon RA, Brouillet D. Compensating for memory losses throughout aging: validation and normalization of the memory compensation questionnaire (MCQ) for non-clinical French populations. Arch Gerontol Geriatr. 2015 Jan-Feb;60(1):28-38. doi: 10.1016/j.archger.2014.10.013. Epub 2014 Oct 22.
Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003 Oct 1;21(19):3557-8. doi: 10.1200/JCO.2003.07.080. Epub 2003 Aug 11. No abstract available.
Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x.
Paquet L, Collins B, Song X, Chinneck A, Bedard M, Verma S. A pilot study of prospective memory functioning in early breast cancer survivors. Breast. 2013 Aug;22(4):455-61. doi: 10.1016/j.breast.2013.04.002. Epub 2013 May 4.
Paquet L, Verma S, Collins B, Chinneck A, Bedard M, Song X. Testing a novel account of the dissociation between self-reported memory problems and memory performance in chemotherapy-treated breast cancer survivors. Psychooncology. 2018 Jan;27(1):171-177. doi: 10.1002/pon.4389. Epub 2017 Feb 10.
Woods SP, Moran LM, Dawson MS, Carey CL, Grant I; HIV Neurobehavioral Research Center (HNRC) Group. Psychometric characteristics of the memory for intentions screening test. Clin Neuropsychol. 2008 Sep;22(5):864-78. doi: 10.1080/13854040701595999.
Razavi D, Delvaux N, Farvacques C, Robaye E. Screening for adjustment disorders and major depressive disorders in cancer in-patients. Br J Psychiatry. 1990 Jan;156:79-83. doi: 10.1192/bjp.156.1.79.
Scullin MK, McDaniel MA, Shelton JT. The Dynamic Multiprocess Framework: evidence from prospective memory with contextual variability. Cogn Psychol. 2013 Aug-Sep;67(1-2):55-71. doi: 10.1016/j.cogpsych.2013.07.001. Epub 2013 Aug 3.
Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995 Apr;39(3):315-25. doi: 10.1016/0022-3999(94)00125-o.
Smith G, Della Sala S, Logie RH, Maylor EA. Prospective and retrospective memory in normal ageing and dementia: a questionnaire study. Memory. 2000 Sep;8(5):311-21. doi: 10.1080/09658210050117735.
Smith T, Gildeh N, Holmes C. The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Can J Psychiatry. 2007 May;52(5):329-32. doi: 10.1177/070674370705200508.
Woods SP, Carey CL, Moran LM, Dawson MS, Letendre SL, Grant I; HIV Neurobehavioral Research Center (HNRC) Group. Frequency and predictors of self-reported prospective memory complaints in individuals infected with HIV. Arch Clin Neuropsychol. 2007 Feb;22(2):187-95. doi: 10.1016/j.acn.2006.12.006. Epub 2007 Feb 6.
Zeintl M, Kliegel M, Rast P, Zimprich D. Prospective memory complaints can be predicted by prospective memory performance in older adults. Dement Geriatr Cogn Disord. 2006;22(3):209-15. doi: 10.1159/000094915. Epub 2006 Aug 7.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PROICM 2018-07 BPR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.